In conclusion, the several novel proposed pre-therapy biologic predictors (CUX1 deletions, allelic state, TP53 splice junction mutations, TP53 VAF, autosomal monosomies, and specific co-mutation patterns) as well as antecedent treatment (HMA exposure) for a myeloid neoplasm have differential prognostic utility depending on treatment subgroups (intensive vs. HMA-based). The gene discussed is TP53; the disease is myeloid neoplasm.